

Emerging Gene Therapies for Sickle Cell Disease

Key Stakeholder Organizations

ICER receives input on its reviews from multiple stakeholders, including patients and their families, patient advocacy organizations, clinicians, clinical societies, insurers, and drugmakers. We invite the public to submit recommendations for key stakeholders in any of these categories. The following is a list of organizations from which ICER has requested input as well as those that have provided public comments during the review. None of these individuals or organizations is responsible for the final content of ICER's report, and it should not be assumed that they support any part of the report, which is solely the work of the ICER team and its affiliated researchers. Furthermore, all of the organizations and individuals below have been invited to provide input, however, it should not be assumed that they have responded to ICER's outreach or agreed to participate in this review.

For a complete list of key dates and opportunities for input on this project, please visit [ICER's website](#).

- American Society of Hematology
- Black Women's Health Imperative
- bluebird bio, Inc
- Children's Hospital of Philadelphia
- Dreamsickle Kids Foundation
- Optum, Inc.
- Partnership to Improve Patient Care
- Sick Cells
- Sickle Cell Association of the Midwest
- Sickle Cell Disease Association of America
- Sickle Cell Disease Association of Illinois

- Vertex Pharmaceuticals
- Young Adult SC Alliance